August 4, 2017 6:09pm
Love the sector upside, but next week brings an onslaught of thirteen (13) Q2 financial results …
Could be a dangerous week …
Pre-open indications: 5 hit and 3 miss
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s investor’s newsletter,” I give you my motivation to focus on factor investing. Companies need to consider how they can perform without headwinds. Tell-tale factors suggest that cheap value and the risk versus reward ratio speak to chase fewer stocks but, understand the macros and micros of our universe.”
- Volume is still very LOW and higher in buying ...
Reiterating, “how many ways can I say it, the cell therapy sector is entering the usual weak seasonal period side-by-side with investor pessimistic views of quarterly financial results. Historically, the period from August through October has seen stocks struggle and a period when corrections have tended to occur more than often.”
Never forget, we are in the middle of Q2 financial result announcements and the pre-release period suffers many a company’s share pricing … thirteen (13) - next week!
Historically, the period from August through October has seen stocks struggle and a period when corrections have tended to occur more than often.
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The first hour was negative with an A/DL of 15/25 and 3 flats;
· The mid-day was positive with an A/DL of 21/19 and 3 flats;
· The close was positive with an A/DL of 24/15 and 4 flats;
Pre-open indications: 5 hit and 3 miss
- Applied Genetic Technologies (AGTC) closed up +$0.50 – hit;
- AxoGen (AXGN) closed down -$0.25 – miss;
- BioLife Solutions (BLFS) closed down -$0.11 – hit;
- bluebird bio (BLUE) closed up $1.65 – hit;
- Cellectis SA (CLLS) closed up +$0.15 – miss;
- Juno Therapeutics (JUNO) closed up +$0.81 – miss;
- Kite Pharma (KITE) closed up +$2.05 – hit;
- Spark Therapeutics (ONCE) closed up +$0.11 – hit;
Daily analytics:
U.S. stocks closed higher on Friday, with the Dow ending at a record for an eighth straight session with gains spurred by the July payrolls report, which showed the U.S. created 209,000 new jobs in July.
- The Dow gained 66.71 points, or 0.3%, to 22,092.81, finishing at its highs of the session, which also represented an intraday record. With the day’s record, it has now posted 34 record closes thus far this year.
- The S&P 500 rose 4.67 points, or 0.2%, to 2,476.83, while the NASDAQ climbed 11.22 points, or 0.2%, at 6,351.56. All three indexes dipped into slightly negative territory within the first hour of trading, but subsequently rebounded, ending near their highs of the session.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded at 10.03 – down -3.93% …
- Thursday traded at 10.44, up +1.56% … after Wednesday traded at 10.24, up +1.49%. Tuesday’s 10.09 down -1.66%, Monday traded 10.30 up +0.10% … as last Friday closed at 10.29 up +1.78
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Friday was up +0.49%
· Thursday down -0.51%
· Wednesday was down -1.07%
· Tuesday was up +0.20%
· Monday down -0.31%
· Last Friday down -0.28%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Friday was up +0.33%
· Thursday -0.79%
· Wednesday was up +0.40% which didn’t help the cell therapy sector
· Tuesday down -1.04%
· Monday down -0.85%
· Last Friday up +0.63%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %’s migrate…
· Friday’s decliners ranged from -0.14% <MDXG> to -13.24% <CUR> in 15 equities;
· Thursday’s decliners ranged from -0.53% <HSGX> to -6.85% <CUR> in 18 equities;
· Wednesday’s decliners ranged from -0.15% <OSIR> to -9.63% <CYTX> in 28 equities;
· Tuesday’s decliners ranged from -0.14% <MESO> to -8.51% <CYTX> in 31 equities;
· Monday’s decliners ranged from -0.03% <IMUC> to -8.16% <FCSC> in 31 equities;
· Last Friday’s decliners ranged from -0.02% <CYTX> to -12,31% <CAPR> in 25 equities;
Versus
………… look at the percentage’s (%) and their decreases …….
· Friday’s gainers ranged from +0.14% <ONCE> to +13.43% <RENE.L> in 24 equities;
· Thursday’s gainers ranged from +0.30% <CLLS> to +10.91% <CAPR> in 20 equities;
· Wednesday’s gainers ranged from +0.64% <QURE> to +19.72% <ONCE> in 14 equities;
· Tuesday’s gainers ranged from +0.87% <BLFS> to +5.08% <FCSC> in 8 equities;
· Monday’s gainers ranged from +0.49% <VTGN> to +4.64% <AXGN> in 9 equities;
· Last Friday’s gainers ranged from +0.27% <XON> to +11.92% <KOOL> in 16 equities;
Some of MY working trend lines or indications:
… The greatest volume to the downside: CUR, MDXG, IMUC, NWBO and CYTX
… Upside volume was weighted to: ONCE, JUNO, ONVO, SGMO and BLUE
… Biggest $ downside: MESO, AXGN, OSIR, CUR and BLFS
… Largest $ upside: KITE, BLUE, JUBO, BLCM and AGTC
… Flat: KOOL, VSTM, ISCO, OPXA
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
